Founded in 1993
  Year: 2007 | Volume: 15 | Issue: 1-2 | Pages: 28-35
  Review Article
Baltic V, Baltic M.
  DOI: 10.2298/AOO0702028B
  Nowadays, in genomocentric era accelerated research of the human genome coupled with advances is enabling the comprehensive molecular profiling of human tissue. Particularly, DNA microarrays are powerful tools for obtaining global view of human non-Hodgkin lymphomas gene expression. Complex information from lymphomas “expression profiling” studies can, in turn, be used to create molecular markers that have diagnostic or prognostic implications. The gene „expression profiling” is not of routine clinical oncology practice, but is used in genomic classification of clinically relevant subgroups of non-Hodgkin lymphoma. The genomics biomarkers have been incorporated into current prognostic models which are based on IPI, R-IPI, and FLIPI. Molecular or pharmacogenomic profiling can be used as new therapeutic targets for patients who are refractory to current therapy. We discus the utility of DNA microarray- based lymphoma profiling in clinical oncology research, and identify future of research in lymphoma evolving fields.
  Key words: Gene Expression Profiling; Microarray Analysis, Lymphoma, Non-Hodgkin; Prognosis; Survival
  Read full text in PDF [Full Text]
Next article

Previous article

Table of contents

Browse all Volumes

Search all Volumes
By keywords
By authors

  Search AoO for:

  Related articles in AoO:
About Journal | Editorial Board | Editorial Policy | Instructions for Authors | Open Access | Advertising | Payed issues | Article Submission Charge | Contact
Founder, owner and publisher: Oncology Institute of Vojvodina, Serbia
Online since 1997 (Abstracts only); 2000 (Abstracts and Full text)
ISSN: 0354-7310 eISSN: 1450-9520